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Summary Subcutaneous and intracranial VMDk tumours were treated with photodynamic therapy (PDT)
using a new sensitiser, m-THPP. Subcutaneous tumours were highly sensitive to PDT but intracranial tumours
were much more resistant, requiring a 30-fold increase in sensitiser dose to produce equivalent levels of
necrosis. Resistance of intracerebral tumours was not due to failure of the sensitiser to enter tumours. Necrosis
of intracranial tumours was increased when mice breathed 100% oxygen during PDT while subcutaneous
tumour necrosis was unaffected.
Malignant astrocytic tumours, glioblastoma multiforme and
malignant astrocytoma, run a particularly aggressive course;
median survival after surgery being less than 1 year (Walker
et al., 1980; Salcman, 1980). They do not metastasise and
death is most commonly due to local recurrence of the
tumour. Therefore, any improvement in local control would
be expected to prolong survival. Photodynamic therapy
(PDT) was proposed as an adjuvant therapy for the treat-
ment of human brain tumours, after removal of the bulk of
the tumour by radical surgery. PDT relies on the fact that
certain systemically administered photosensitisers localise in
and are retained by tumours (and also normal tissues). Expo-
sure of the tumour to light which activates the photosen-
sitiser leads to rapid necrosis, which is probably due to cell
membrane damage by singlet oxygen (Moan et al., 1979).
Brain tumours may be good candidates for PDT as photo-
sensitisers so far investigated do not cross the blood brain
barrier (BBB), but accumulate in brain tumours, which lack
an effective barrier. Thus, administration of a photosensitiser
before surgical debulking of the tumour, followed by illu-
mination of the tumour bed to destroy remaining tumour
cells, may conceivably eradicate the tumour.
Initial applications of PDT to brain tumours in man pro-
duced equivocal results (Perria et al., 1980; Laws et al., 1981;
McCulloch et al., 1984). Treatment protocols varied widely
and, though there were some remissions, rapid tumour reg-
rowth often occurred. Recent trials using more intensive PDT
regimens have produced more promising results (Kaye &
Morstyn, 1987; Muller & Wilson, 1987; Kaye, 1989), and
have stimulated renewed interest in this treatment.
Animal experiments have shown that, with the photosen-
sitisers available for clinical use, haematoporphyrin derivative
(HpD) and Photofrin II, PDT treatments which produce
tumour kill also cause severe cerebral oedema and necrosis of
normal brain (Rounds et al., 1982; Bonnett et al., 1984),
which is probably due to damage to the endothelium of small
blood vessels (Berenbaum et al., 1986). Cerebral oedema
resulting from PDT has been reported in man (Muller &
Wilson, 1987; McCulloch et al., 1984). It has been success-
fully controlled with intra/post-operative steroids (Kaye &
Morstyn, 1987), but the possibility that PDT may damage
normal brain is worrying. Clearly, new photosensitisers are
required which do not sensitise normal brain. The meso-tetra
(hydroxyphenyl)porphyrins have been shown to be potent
sensitisers of subcutaneous tumours at doses which cause
little damage to normal brain (Berenbaum et al., 1986). We
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have therefore used the meta-isomer m-THPP in the treat-
ment of subcutaneously and intracranially transplanted
VMDk mouse gliomas (Bradford et al., 1987; Bradford et al.,
1989). Further, in view of the evidence for oxygen depend-
ency of PDT in vitro (Lee See et al., 1984; Moan & Sommer,
1985) and in vivo (Henderson & Fingar, 1987; Gomer &
Razum, 1984) we have studied the effect of PDT on tumours
in animals breathing either air or 100% oxygen.
Materials and methods
Animals
Male and female mice of the VM strain, weighing 20-25 g,
were used in all experiments. Mice were housed in standard
cages and received food and water ad libitum.
Tumour model
The VMDk mouse glioma is a transplantable tumour derived
from a spontaneously occurring astrocytoma of VM mice
(Fraser, 1971). The P497(pl) cell line of this tumour was
used between passage levels 10 and 16 (Bradford et al., 1987).
Tissue culture
Cells were cultured in plastic tissue culture flasks in HAMS
FIO medium (Gibco) with 10% foetal calf serum (Imperial).
Flasks were incubated at 37'C until near-confluent mono-
layers had formed. Cells were removed by trypsinisation
(0.25% in Hanks balanced salt solution, Flow), resuspended
in medium and centrifuged at 220 g for 5 min, and the pellet
then resuspended in medium to form a single-cell suspension.
Subcutaneous tumours
Four x 106 cells in 0.1 ml medium were injected subcutan-
eously into the flank. Tumours were treated when their max-
imum depth was 5.3 ± 0.21 mm (s.e.), n = 47. They were
spherical or ellipsoidal, with a volume of about 70-90 cu
mm.
Intracranial tumours
Medium containing I x 106 cells 10 A' was drawn into a
Hamilton syringe mounted on a micromanipulator (Nari-
shige, Japan). Mice were anaesthetised with Equithesin
(Green, 1979) diluted 1:3 in physiological saline at a dose of
0.1 ml Og-' body weight i.p. The scalp skin was incised
from between the ears to the snout, and a 3 mm diameter
craniectomy was formed in the left parietal bone using a
small dental drill and burr. Ten lil of tumour cell suspension
was injected into the cortex 1 mm from the midline, at a
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depth of 2 mm from the brain surface. The scalp skin was
then resutured. Tumours were treated 7 days after implanta-
tion, when they were approximately 2 mm in diameter, i.e.
about 4 cu mm in volume, and showed numerous mitotic
figures. In the great majority, the tumour centre was ver-
tically beneath the craniectomy site.
Photosensitiser
m-THPP (5,10,15,20-tetra-(m-hydroxyphenyl)porphyrin), was
prepared as previously described (Bonnett et al., 1987; Beren-
baum et al., 1986) and dissolved to the required concen-
tration in 0.05 M sodium hydroxide. Photosensitiser was
administered on a mole kg-' basis (molecular weight 680), by
intravenous injection of 0.1 ml 10g-' body weight into the
tail vein under brief halothane anaesthesia.
Light source
A CUIO copper vapour laser, pumping a DL 10K dye laser,
was used (Oxford Lasers). The dye was rhodamine 640. Light
was directed down a 1 mm diameter fibre which had a 300
divergence at the tip. Light intensity was measured with a
14BT thermopile (Oxford Instrumentation), and was kept
below 300 mW cm-2 to avoid thermal effects. The excitation
wavelength used for m-THPP was 648 nm.
Photodynamic therapy
Subcutaneous tumours PDT treatment and measurement of
tumour necrosis have been described in detail (Berenbaum et
al., 1982). With the light-delivery fibre positioned vertically
above the tumour centre, tumours were illuminated with
1OJ cm-2 light 24 h after injection of photosensitiser in doses
of 0.78-2.2 ftM kg-'. The following day, 0.2 ml of 1% Evans
blue (Sigma) in physiological saline was injected i.v. and 1 h
later the tumours were removed into formol saline. Thick
sections of fixed tumour were cut in a direction parallel to
the light beam. The depth of necrosis was measured under a
dissecting microscope fitted with an eyepiece graticule.
Intracranial tumours Tumour-bearing mice were injected
with photosensiter in doses of 6.25-25 zlM kg-'. Twenty-four
hours later they were anaesthetised with Equithesin and the
scalp skin incised. With the fibre positioned vertically above
the craniectomy site, the left half of the cranium was illum-
inated, the opposite side being protected from the light with
a black shield. Light doses were 10-20J cm-2. The scalp skin
was then resutured. Twenty-four hours later mice were
injected with 0.2 ml of 2% Evans blue in 10% bovine serum
albumen (BSA) in saline and sacrificed 1 h later. Brains were
removed into formol saline and paraffin-embedded sections
were stained with haematoxylin and eosin.
Assessment ofextent oftumour necrosis
PDT-induced necrosis of subcutaneous (s.c.) tumours was on
the skin side of the tumour, fairly homogeneous and clearly
demarcated from non-necrotic tumour. Thus, depth of the
necrotic layer was a suitable parameter for assessing the
extent of damage. In contrast, necrosis in intracranial (i.c.)
tumours was usually irregularly distributed and these
tumours grew at varying depths within the brain, so depth of
necrosis was not a suitable measure of damage. Instead, we
measured the fraction of the tumour section area that was
necrotic. This was determined by projecting the image of the
section onto paper using a projection microscope (Reichert,
Austria) and measuring the projected areas corresponding to
necrotic and non-necrotic tumour. In order to equate the
damage assessments in s.c. and i.c. tumours, the fractional
area of necrosis was also calculated for s.c. tumours. The
cross-sections of these tumours were approximately elliptical
or circular with the necrotic area comprising a segment
delineated by a fairly straight line. Thus, the fraction A of
the area that was necrotic could be calculated as
A = I [cos'la-al -a2]
where a = 1- 2d/D, D being the maximum depth of the
tumour and d the depth of necrosis.
PDT with oxygen supplementation
Anaesthetised animals were put into a sealable chamber with
gas inlet and outlet points through which 100% oxygen was
circulated at a flow rate of 1 litremin-'. Individual animals
were removed from the chamber for PDT during which
oxygen continued to be administered via a face mask. The
total time of oxygen administration was 5-7 min.
Photosensitiser extraction
Mice were injected with 50ltM kg-' m-THPP i.v. From this
time they were kept in subdued light to prevent photo-
dynamic skin damage. There were sacrificed at intervals from
5 min to 10 days after injection. Tissue samples were col-
lected and stored at -20°C until required. Sensitiser was
extracted from serum, normal brain, brain tumour and sub-
cutaneous tumour. The quantities used for extraction were
0.2 ml serum, the whole brain (c. 400 mg), whole i.c. tumours
(30-200 mg) and whole s.c. tumours (150-500mg). The tis-
sue of interest was macerated in 2 ml acetone and left to
extract for 24 h in sealed glass centrifuge tubes. Samples were
centrifuged at 200 g for 5 min and the supernatants collected.
Absorbances at 415 nm were measured on a spectrophoto-
meter (Philips PU 8620). Sensitiser concentrations were ex-
pressed as fsgg-' tissue or ytgml-' serum, using m-THPP
solutions of known concentration dissolved in 80% acetone/
20% normal saline for calibration. Preliminary experiments
(not described here) had shown that 95% of sensitiser was
extracted by this procedure. Normal brain sensitiser levels
were corrected for blood content which, in the mouse, is
about 2% of the brain volume (Levin et al., 1984). Brain
tumour sensitiser levels were corrected for contamination of
the excised tissue by normal brain in the following way. Mice
bearing i.c. tumours received 0.2 ml of 2% Evans blue in
10% BSA in saline i.v. 1 h before sacrifice. Brains were
removed and put at - 20°C. When they were semi-frozen the
blue stained tumours were excised and fixed in formol saline.
Measurements on paraffin-embedded sections stained with
haematoxylin and eosin showed 0.78 of the area of excised
tissue to be tumour and 0.22 to be brain (n = 12, s.e. = 0.05).
Thus, the fractional volume ofexcised tissue that was tumour
was 0.783/2, or 0.69. The concentration of sensitiser in tumour
was then calculated as (T-0.31N)/0.69, where T was the
concentration measured in the whole excised sample and N
the concentration in normal brain.
Results
PDT-induced necrosis ofs.c. and i.c. tumours
Subcutaneous VMDk tumours were highly sensitive to PDT.
Low doses of sensitiser (2.2iLmkg-') and light (1OJcm2)
produced necrosis down to a mean depth of 7.5 mm which,
in these tumours, represented complete necrosis (Figure 1).
Thus, the subcutaneous VMDk tumour is even more sensi-
tive to PDT than the PC6 tumour reported previously, where
2.2tLM kg-' m-THPP with 1OJ cm-2 produced only 1-2 mm
necrosis, and necrosis 7.5 mm deep required a dose of about
25tLM kg-' (Berenbaum et al., 1986). In contrast, intracranial
tumours were highly resistant to PDT. With a light dose of
1OJ cm-2 no necrosis was produced at doses of 12.5jLM kg-'
or less and, even at the maximum sensitiser dose tolerated
with this light regime, 25tAM kg-', less than 10% of the
tumour became necrotic (Figure 1).
Effect ofoxygen breathing
When mice breathed 100% oxygen instead of air immediately
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substantially increased (Figure 1). For example, 12.5 IAM kg-'
m-THPP and 20Jcm-2 produced only 10% necrosis in air-
breathing mice but produced 60% necrosis in oxygen-breath-
ing mice. Nevertheless, the sensitivity of intracranial tumours
was far from being brought up to the level of subcutaneous
tumours by oxygen breathing. For example, 60% necrosis
was produced in subcutaneous tumours (with 1OJ cm-2) at a
dose of about 1.4ftM kg-' of sensitiser but, in intracranial
tumours (with 20J cm-2), this required a dose of 12.5IM
kg-1; a nine-fold increase in sensitiser dose and a doubling of
the light dose. The use of oxygen with PDT did not change
the irregular pattern of necrosis of i.c. tumours. Oxygen
breathing did not affect the sensitivity of subcutaneous
tumours (Figure 1).
Photosensitiser levels
After an initial rapid fall, presumably due to loss to the
extravascular space, serum levels of m-THPP fell with an
initial half-life of about 1 day which was then prolonged to
about 4 days (Figure 2). Brain levels (corrected for blood
content) fell initially, but then remained almost constant
from 8 h to 10 days. At 24 h, brain levels were 1% of serum
levels, confirming exclusion of the sensitiser by the BBB. One
day after photosensitiser injection (the usual time for photo-
therapy) the level of m-THPP in i.c. tumours was about 100
times that in normal brain, confirming the lack of any effect-
ive barrier to the drug in the tumour. When drug levels were
matched against tumour size (Figure 3), it was found that the
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Figure 1 Fractional area of tumour necrosis and depth
of tumour necrosis ......... in subcutaneous and intracranial
tumours in mice breathing air (solid symbols) or oxygen (open
symbols). Tumours were exposed to lOJ cm-2 (0, *) or to
20J cm-2 (0, *), 24 h after sensitisation with a range of doses of
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Figure 3 Levels of m-THPP in individual subcutaneous 0 and
intracranial * tumours, 24 h after injection with 50iLM kg-'
m-THPP.
concentration of sensitiser in i.c. tumours was about half that
in s.c. tumours of corresponding size. In s.c. tumours, drug
concentration was inversely correlated with tumour size,
fitting the equation, concentration = 46.7-0.06 weight, with a
correlation coefficient r = 0.86 (n = 15). No such correlation
was found for intracranial tumours (concentration = 27.9-
0.03 weight, r = 0.2 (n = 8), but lack of correlation may have
been due to the small sample size or to the small range of
tumour sizes that could be examined.
Discussion
Two questions are raised by this study, both of which might
be relevant to the treatment of brain tumours in man. (1)
Why are intracranial implants of the VMDk glioma much
more resistant to PDT than subcutaneous implants? (2) Why
is sensitivity of intracranial VMDk tumours increased by
oxygen breathing, whereas that of subcutaneous tumours is
not? A number of possibilities may be considered:
(a) Light penetration and tumour geometry
The possibility that insufficient light penetrates to reach
intracranial tumours does not warrant serious consideration
as brain is among the most translucent of tissues (Svaasand
& Ellingsen, 1983, 1985; Muller & Wilson, 1987). Differences
in tumour geometry, for example, in tumour depth in the
tissue, would certainly affect light penetration, but any effect
on sensitivity of intracranial compared with subcutaneous
tumours would have produced a differential the reverse ofthe
one we observed. Subcutaneous tumours almost always
extended deeper from the surface than intracranial tumours
(Figure 1 shows that with 2.2gM kg-' of sensitiser, tumour
necrosis was 6-8 mm deep, as compared with a depth of
only 5-6 mm for the whole mouse brain). Thus, intracranial
tumours must have been subject to substantially higher space
irradiance than subcutaneous tumours and, had tumour geo-
metry been an important factor, the former should have been
more, not less, sensitive than the latter.
(b) The Blood-Brain Barrier
The possibility that the sensitiser is prevented by the BBB
from entering intracranial tumours may be dismissed out-
right, for we found the levels in these tumours to be about
50% of those of subcutaneous tumours of similar size,
although very little enters normal brain (Figure 2). If i.c. and
s.c. tumours had been equally sensitive, the reduction in
sensitiser levels in i.c. as compared with s.c. tumours should
have been overcome by a doubling of the sensitiser dose,
whereas we found the increased required to be 30-fold.
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(c) Distribution ofsensitiser
Another possibility to be considered is that the sensitiser is
irregularly distributed in intracranial tumours (perhaps
because of irregularly distributed BBB impairment), and thus
there would be an irregular and limited distribution of
damage. The experiments of Tator (1976) are of interest here.
He administered radiolabelled methotrexate to mice bearing
intracranial or subcutaneous implants of an ependymoblas-
toma, and found that labelled drug was present in the central
portion of intracranial tumours, but at lower levels than in
subcutaneous tumours. Possibly relevant is that, while distri-
bution of the label was uniform in subcutaneous tumours, it
was irregular in intracranial tumours; for example, a large
intraventricular deposit contained almost no drug. However,
this explanation for our findings would require most of the
sensitiser to be concentrated in 10% of the tumour, which
would imply a concentration in these regions about eight
times higher than in non-barrier sites, such as s.c. tumours.
This does not seem plausible.
(d) Hypoxia
It is possible that i.c. tumours are significantly more hypoxic
than s.c. tumours, which would greatly reduce their sensi-
tivity to PDT (Gomer & Razum, 1984; Henderson & Fingar,
1987). At first sight this seems unlikely as intracranial
tumours were still very small at the time of treatment (mean
volume 4cu mm) and brain has a copious blood supply. In
contrast, subcutaneous tumours were used at a mean volume
of about 70-90 cu mm and subcutaneous tissue is by no
means as well vascularised as brain. However, it may be that
blood entering intracranial tumours is relatively oxygen-
depleted due to the high oxygen demand of surrounding
normal brain. In contrast, subcutaneous tissue does not have
high oxygen requirements, allowing well oxygenated blood to
pass into s.c. tumours. This difference might well be exacer-
bated by the hypoxia induced by anaesthesia in the mouse.
This hypothesis is supported by the fact that oxygen breath-
ing substantially increased the photosensitivity of i.c.
tumours but did not affect that of s.c. tumours. Oxygen may
therefore be a limiting factor for PDT of i.c. tumours, but
not for that of s.c. tumours. However, this explanation also
leaves much to be desired for, although oxygen breathing
increased the photosensitivity of i.c tumours, there remained
a striking disparity in sensitivity between the two sites. It
may be postulated that this high resistance to PDT in i.c.
tumours, even when oxygen was administered, is due to a
marked inadequacy in the vasculature of i.c. tumours which
limits the entry of oxygen, but this seems unlikely in such
small tumours. Clarification of the oxygenation state of
tumours requires direct measurement of tissue oxygen levels
and these investigations are under way.
In summary, we have as yet no convincing explanation for
the marked difference in photosensitivity between s.c. and i.c.
VMDk tumours. In practical terms, our findings suggest that
destruction by PDT of brain tumours might be modestly
increased by the administration of oxygen at the time of
treatment. However, the effects of this on photosensitisation
of normal brain need to be investigated.
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